MSH2 and cancer: Of further relevance, the incidence of cancer in individuals carrying a fully inactivating PMS2 variant is lower than that in individuals carrying a fully inactivating MSH2 or MLH1 variant, which results from the partial genetic redundancy of PMS2 with minor MMR proteins (notably MLH3 or PMS1).